DENGUE-IMPFSTOFFFORMULIERUNG

European patent · EP4356925 · In force

Register entry

Publication number
EP4356925
Application number
EP23204288
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Oct 18, 2023
Published
Apr 24, 2024
Granted
Sep 10, 2025
Protection ends at the latest
Oct 17, 2043
Next annual fee due
Oct 31, 2026
IPC classes
A61K 39/12 (2006.01)
A61K 9/19 (2006.01)
A61K 39/295 (2006.01)
A61K 47/00 (2006.01)
A61K 47/02 (2006.01)
A61K 47/10 (2017.01)
A61K 47/16 (2006.01)
A61K 47/18 (2017.01)
A61K 47/26 (2006.01)
A61K 47/64 (2017.01)
A61K 39/00 (2006.01)
A61K 39/39 (2006.01)
Priority
EP 22202112 18.10.2022
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 22, 2026

    Change

    Published in Swissreg on 22.07.2026

  2. Oct 3, 2025

    Agent entered

    Representative
    Stolmár & Partner Intellectual Property S.à.r.l., Bahnhofstrasse 11, 6210 Sursee

    Published in Swissreg on 03.10.2025

  3. Sep 10, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 10.09.2025

Parties

Holder

Takeda Vaccines, Inc.

75 Sidney Street, Cambridge, MA 02139, US

Agent

Stolmár & Partner Intellectual Property S.à.r.l.

Bahnhofstrasse 11, 6210 Sursee

Inventor

KOMMAREDDY, Sushma

Cambridge, 02139, US

YAZDI, Sara

Cambridge, 02139, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.